Pregabalin Capsule
Product Images NDC 70518-3597

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a prescription medication called Pregabalin with a strength of 75 mg. The package contains 90 capsules and should be stored in tight containers at a temperature between 15-30°C. It is manufactured by Ascend Labs, LLC in Montvale, NJ and repackaged by RemedyRepack Inc. Detailed directions are provided in the package insert. The expiration date and lot number are not available in this text.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This appears to be a calculation formula for estimating creatinine clearance (CLCr), which is a measure of kidney function. The formula takes into account the patient's age, weight, and serum creatinine levels. However, the text is incomplete and lacks further context, therefore it is difficult to provide a full description or interpretation of its use.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

The text describes the results of two studies (Study E1 and Study E3) on a certain treatment. The text includes percentages and numeric values for different dosages of the treatment and the placebo. The text also mentions that the treatment was found to be statistically significant compared to the placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

This is a statistical table with different p-values and values related to different studies. The data seems related to clinical trials testing the efficacy of a drug. The only information provided is the significant p-values. Therefore, it is not possible to provide a detailed description or conclusion about the study or the drug.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

Percentage improvement in pain from baseline. The rest of the text is not readable or available.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

This is a chart showing the percent improvement in pain for patients taking different doses of Pregabalin. The highest improvement was seen in patients taking a 600mg daily dose, followed by those taking a 450mg daily dose, then a 300mg daily dose, and finally patients taking a placebo. No further information is available.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.